New antibiotic shield for kids battling leukemia
NCT ID NCT06810583
Summary
This study is testing whether a long-acting antibiotic called dalbavancin, given every 28 days, can prevent serious bloodstream infections in children and young adults with high-risk leukemia who are receiving intense chemotherapy. The trial will enroll up to 29 participants to see how well the body processes the drug and how safe and acceptable this preventive approach is. The main goal is to see if this method lowers the rate of dangerous bacterial infections compared to older prevention strategies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.